Background Diverticulitis is a common gastroenterological condition with significant symptomatic burden for affected patients. Historically, patients with uncomplicated diverticulitis were treated with antibiotics. Recent data suggests antibiotics may be unnecessary for patients with acute uncomplicated diverticulitis, shifting US clinical guidelines towards an antibiotic-sparing approach. Despite this evidence, there remains a lack of adoption of these guidelines.

Purpose This qualitative study aims to identify barriers and facilitators regarding the de-implementation of antibiotics in management of acute uncomplicated diverticulitis.

Methods Semi-structured interviews were conducted with both emergency medicine and primary care providers from October to November 2024. Providers were recruited through email with snowball sampling. Prior to interviews, demographic data was collected through a REDCap survey. Interviews focused on personal experience treating patients with acute uncomplicated diverticulitis and perceived barriers and facilitators for de-implementation of antibiotics. Thematic saturation was reached within the sample size. Interviews were transcribed and qualitatively analyzed using an iterative inductive/deductive approach.

Results Twenty-six providers were interviewed: 12 from primary care and 14 from emergency medicine. Transcripts from interviews were qualitatively analyzed to create an integrative model of barriers and facilitators. Prevalent barriers integrated into the model included systemic factors such as lack of proper follow-up, social influences such as patient expectation of antibiotics, and provider factors such as unawareness of guidelines and studies. Prevalent facilitators included antibiotic stewardship and clinical pathways to guide treatment decisions.

Conclusion This qualitative study identified actionable barriers and facilitators from the perspective of providers regarding de-implementation of antibiotics for acute uncomplicated diverticulitis. Next steps include the development of de-implementation efforts addressing these results, including educational sessions for providers, public health initiatives for patients, enhanced clinical pathways to inform treatment decisions, and antibiotic stewardship feedback on prescription patterns.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This Institutional Review Board of Vanderbilt University Medical Center waived ethical approval for this work. A waiver for informed consent was granted from the Institutional Review Board as well.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.